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Restenosis is currently the major limitation of percutaneous transluminal coronary angioplasty
(PTCA). Factors such as elastic recoil, migration of vascular smooth muscle cells from media
to intima, neointimal proliferation and vascular remodeling underly the restenotic process.
Presently there is no effective therapy available for restenosis. The role of platelets in the
development of thrombosis and abrupt closure after PTCA is well recognized. However, the
effects of platelets in PTCA extend well beyond the early phase. Although antiplatelet agents
such as glycoprotein IIb/IIIa antagonists have been reported to reduce target vessel
revascularization, major unresolved controversies still exist. This report reviews the potential
role of platelets in restenosis. Various drugs, successfully tested in experimental studies and in
a small number of human studies, that inhibit the effect of platelets on the restenotic process
are also reviewed. (J Am Coll Cardiol 2000;35:555–62) © 2000 by the American College of
Cardiology
The utility of percutaneous transluminal coronary angio-
plasty (PTCA) has been established since the technique was
reported in 1978 (1). Presently the primary limitation of
PTCA appears to be restenosis (defined as .50% diameter
stenosis on follow-up angiography), seen in up to 30% to
40% of patients (2). Restenotic lesions are histopathologi-
cally different from primary atherosclerotic lesions: compar-
atively, significantly greater smooth muscle cell (SMC)
hyperplasia and less densely layered collagen and degener-
ating tissue have been observed in restenotic lesions (3).
Restenosis is considered to occur over three phases: phase
I 5 elastic recoil within 24 h; phase II 5 mural thrombus
formation and organization within two weeks; and phase
III 5 neointimal proliferation and extracellular matrix
synthesis within three months (2). Inadequate compensa-
tory enlargement of a vessel after angioplasty (inadequate
vascular remodeling) is also considered important in resten-
osis (4). Inadequate arterial remodeling may be reduced to
an extent by coronary stenting (5). However, a permanent
metallic prosthesis does not reduce neointimal proliferation,
which is considered to be the primary mechanism of
restenosis after stenting (6).
PLATELETS AND PATHOPHYSIOLOGY OF RESTENOSIS
Platelet activation. In an animal model of angioplasty,
platelet deposition was noted to occur immediately after
injury and was undetectable by seven days; SMC migration
and proliferation in media have been noted as early as 36 h
after arterial injury (7) and occur within seven days (8).
Platelets were found to relate directly to intimal prolifera-
tion after arterial injury, and severe thrombocytopenia in-
hibited intimal thickening, an effect that correlated with the
degree of thrombocytopenia (9). After arterial injury, plate-
lets rapidly adhere to the site of injury by several adhesion
receptors: thromboxane A2 is generated, changes in the
glycoprotein (GP) IIb/IIIa complex occur, which then bind
to fibrinogen, subsequently leading to platelet aggregation
and activation (10). Activated platelets release, among other
factors, platelet-derived growth factor (PDGF), a potential
SMC mitogen (11). Figure 1 summarizes the potential
platelet-derived factors that are known to play a role in
neointimal proliferation after balloon injury.
Role of PDGF. Platelet-derived growth factor is the most
important growth factor released by activated platelets. The
association between PDGF and vascular SMC proliferation
has been demonstrated in animal experiments (12) in which
the rise and augmented levels of PDGF-B after arterial
injury correlated with neointimal cellular proliferation. Be-
sides inducing proliferation, the primary effect of PDGF on
vascular SMCs could be the induction of migration, as
PDGF is the strongest reported chemoattractant for vascu-
lar SMCs (13). Platelet-derived growth factor is postulated
to act through autophosphorylation of PDGF receptor,
leading to activation of tyrosine kinase and phosphorylation
of exogenous proteins (12,14), culminating in new deoxyri-
bonucleic acid (DNA) synthesis. Mitogen-activated protein
kinase pathways may also be involved (15).
Effect of other platelet-derived factors. The expression of
transforming growth factor-beta (TGF-beta) is reported to
be increased in atherosclerotic vessels of rabbits after balloon
injury (16). Also, direct transfer of TGF-beta1 gene into
porcine arteries resulted in intimal hyperplasia and increased
extracellular matrix production (17). Serotonin and throm-
boxane A2 are released by activated platelets and promote
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SMC proliferation, both alone and synergistically when
combined together (18). However, in human trials, throm-
boxane A2 receptor antagonists did not show a beneficial
effect on restenosis (19). P-selectin is a glycoprotein stored
in alpha-granules of platelets, expressed on activation of
platelets. It is implicated in platelet-leukocyte interactions,
and decreased neointimal formation has been demonstrated
in P-selectin–deficient mice (20). Histamine released from
activated platelets at the site of vascular injury has been
postulated to induce intimal hyperplasia through H1 recep-
tors (21). Interleukin-1 derived from platelets increases
production of interleukin-6 and interleukin-8, which are
important mediators of inflammation at the site of vascular
injury (22). Although platelet-activating factor induces pro-
liferation in SMC cultures (23), it has been demonstrated to
have no influence on restenosis (24).
Platelets, when activated, can enhance thrombin genera-
tion by five- to sixfold (25). Thrombin, a powerful mitogen,
contributes to SMC proliferation by inducing platelet re-
lease of PDGF (26). Thrombin may also exert a direct
mitogenic stimulation on vascular SMCs (27). During
organization of thrombus, thrombin becomes bound to
extracellular matrix and remains in its active form (28),
being released gradually to exert a prolonged effect on SMC
proliferation. These effects could be of significance, as
increased thrombin generation has been demonstrated after
PTCA in humans (29).
Influence of platelet function and size on restenosis.
Platelet reactivity and size also appear to influence restenosis
after arterial injury. By stepwise regression analysis, abnor-
mal platelet reactivity (defined as platelet reactivity index
.1.07) before PTCA was reported as an important factor in
the development of restenosis (30); restenosis at six months
was seen in 25% of patients with normal platelet reactivity,
50% of patients with mildly abnormal platelet reactivity and
60% of patients with frankly abnormal platelet reactivity
(30% for the entire group). A significant positive correlation
between mean platelet volume and restenosis has also been
reported, with a relative odds ratio of 10.2 for the develop-
ment of restenosis if the mean platelet volume was in the
upper rather than the lower quartile (31).
Effect of exposure to contrast agent and artificial surface.
Platelet function can be influenced by the type of contrast
agent used. In an in vitro study, nonionic contrast medium
showed an increased incidence of platelet degranulation;
this event could contribute to restenosis by promoting
increased local release of procoagulant molecules and
PDGF (32). Increased platelet activation, demonstrated in
in vitro experiments using stents, is postulated to occur
because of exposure to artificial surfaces and shear forces of
stent meshes (33). In human studies after intracoronary
stenting, increased platelet activation has been found to
correlate significantly with restenosis (6). In this study, a
significant increase in GPIIb/IIIa ligand binding was seen
in patients with restenosis as compared with patients with-
out restenosis. Patients with restenosis also showed higher
P-selectin expression and GPIIb/IIIa activation.
Platelets and high risk patients. Certain patient groups,
such as those with diabetes mellitus, chronic renal failure or
hyperlipidemia, are at a higher risk for restenosis. Interest-
ingly, abnormal platelet function has been noted in all of
these disorders. Elevated platelet counts and decreased
nitric oxide synthase activity in platelets have been demon-
strated in patients with diabetes (34,35). Increased platelet
turnover and activation occur in patients with renal failure
who have had long-term hemodialysis (36). Hyperlipidemia
is associated with platelet hyperactivity (37), and antilipemic
therapy has been shown to improve platelet function (38).
The role of platelets in increasing restenosis in these high
risk patient groups merits investigation.
Platelets and remodeling. Arterial remodeling is an im-
portant mechanism of restenosis (4), particularly in nonstent
interventions. Platelets can adversely affect the process of
remodeling after PTCA. Long-term treatment with PDGF
Abbreviations and Acronyms
AS-OLN 5 antisense oligonucleotides
DNA 5 deoxyribonucleic acid
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mRNA 5 messenger ribonucleic acid
PDGF 5 platelet-derived growth factor
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TGF 5 transforming growth factor
Figure 1. Schematic representation of platelet-derived growth
factors involved in neointimal proliferation after vascular injury.
TxA2 5 thromboxane A2; vWF 5 von Willebrand factor.
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has been shown to induce negative remodeling in porcine
coronary arteries (39), and increased PDGF activity has
been implicated in impaired vascular remodeling contribut-
ing to restenosis after coronary atherectomy in humans (40).
Activation of tyrosine kinase of the PDGF receptor (39)
and PDGF-induced increased cytosolic calcium concentra-
tion (41) are some of the mechanisms considered to be
responsible.
ANTIPLATELET THERAPY
FOR DECREASING RESTENOSIS
Various modalities of treatment, such as brachytherapy
(42,43), inhibition of proto-oncogenes (44) and viral vectors
for arterial gene transfer (45), have been reported to de-
crease SMC proliferation and reduce restenosis. Many
antiplatelet agents have also been successful in reducing
SMC proliferation after arterial injury.
ANTIPLATELET COMPOUNDS
Several antiplatelet agents have been investigated for the
prevention of restenosis. In a randomized trial, the combi-
nation of aspirin and dypridamole was found to have no
significant effect on restenosis (46). Likewise, ticlopidine
did not show a beneficial effect in reducing target vessel
revascularization or restenosis in the Intracoronary Stenting
and Antithrombotic Regimen (ISAR) trial (47). Recently, a
new antiplatelet agent, clopidogrel, has been reported to be
a safe alternative to ticlopidine (48); its influence on
restenosis is not yet known. The utility of a monoclonal
antibody to prevent platelet aggregation was first reported
by Coller (49). The murine/human chimeric monoclonal
antibody fragment, c7E3 Fab, has been shown to inhibit
thrombin formation, reduce the need for target vessel
revascularization by inhibiting activated platelets after
PTCA (50,51) and decrease the frequency of ischemic
events after coronary stenting (52). The favorable effect of
c7E3 Fab in reducing the need for target vessel revascular-
ization after PTCA appears to be sustained at three years
(53). Decreased thrombin generation by c7E3 Fab and its
cross reaction with the vitronectin receptor, avb3, could
contribute to a reduction in the need for target vessel
revascularization (54). A similar finding has been reported
in in vitro experiments (55); c7E3 Fab inhibited thrombin
generation by 45% to 50%, which was similar to the
magnitude of inhibition obtained by combining two differ-
ent antibodies with properties of GPIIb/IIIa inhibition and
avb3 inhibition, respectively. The authors (55) conclude
that c7E3 Fab significantly inhibited thrombin generation
through both GPIIb/IIIa and avb3 blockade. The avb3
integrin also mediates SMC migration (56) and prolifera-
tion (57) in response to vascular injury. Inhibition of avb3
by nonselective antagonists was reported to inhibit neointi-
mal proliferation in animal experiments (58).
Besides GPIIb/IIIa and avb3 blockade, c7E3 Fab de-
creases expression of the leukocyte integrin, Mac-1
(CD11b/CD18), after PTCA (59). After PTCA, expres-
sion of Mac-1 by circulating leukocytes was more marked in
patients who subsequently developed restenosis (60). Ad-
ministration of an antibody against Mac-1 to decrease
adhesion and migration of leukocytes resulted in decreased
intimal hyperplasia after balloon injury in rabbits (61).
Further, blocking adhesion of Mac-1–bearing cells to fi-
brinogen and intercellular adhesion molecule-1 by c7E3 Fab
at the site of vascular injury may lead to a lower injury
response (62). However, despite a multitude of experimental
evidence, the role of c7E3 Fab in reducing restenosis still
remains controversial. The beneficial effects of c7E3 Fab in
reducing the need for target vessel revascularization, as
reported in the Evaluation of IIb/IIIa platelet receptor
antagonist 7E3 in Preventing Ischemic Complications
(EPIC) trial (with angiographic data lacking), were not
reproduced in the subsequent Evaluation of PTCA to
Improve Long-Term Outcome by c7E3 GPIIb/IIIa recep-
tor blockade (EPILOG) (63) and Chimeric 7E3 AntiPlate-
leT in Unstable angina REfractory to standard treatment
(CAPTURE) (64) trials, although the recent Evaluation of
Platelet IIb/IIIa Inhibition in STENTing (EPISTENT)
analysis has reported a lower target vessel revascularization
rate in the subgroup of patients with diabetes treated with
stents plus abciximab as compared with the patients with
diabetes treated with stents alone (65). In the Evaluation of
Reopro And Stenting to Eliminate Restenoses (ERASER)
trial (66), which is the only study of c7E3 Fab using
intravascular ultrasound, no benefit in restenosis was noted.
In a recent study in nonhuman primates, despite an ade-
quate antiplatelet effect (documented by markedly pro-
longed bleeding time), no beneficial effect of c7E3 Fab on
neointimal proliferation, as compared with placebo, could
be demonstrated in both angioplasty- and stent-treated
segments (67).
Another antiplatelet agent, cilostazol, has demonstrated
decreased restenosis in humans. This orally administered
phosphodiesterase type III inhibitor decreases platelet acti-
vation by increasing cyclic adenosine monophosphate con-
centration within platelets; cilostazol also directly inhibits
SMC proliferation (68,69). Other antiplatelet agents that
inhibit platelet adhesion have also been reported to decrease
neointimal proliferation. Nitric oxide donors, which have an
inhibitory effect on platelet aggregation (70), and aurintri-
carboxylic acid, which interferes with the von Willebrand
factor–platelet GPIb/IX interaction, have shown decreased
neointimal proliferation after balloon injury (71).
Platelets as vehicles for local drug delivery. Platelets are
biodegradable and exhibit target localization at the site of
arterial injury. Attempts are being made to use these
properties to deliver drugs locally to reduce restenosis. The
platelet membrane can be reversibly permeabilized by elec-
troporation. By using platelets loaded with iloprost (a
prostacyclin analogue), significant reductions in intimal area
and intima/media ratios after angioplasty have been dem-
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onstrated in pig carotid arteries (72). This effect was greater
than that with local delivery of free iloprost. Similar in vitro
results have been reported using iloprost-encapsulated platelets
(73). Inhibition of thromboxane A2 produced by activated
platelets could also contribute to the effect of iloprost.
ANTI-PDGF AGENTS
Many strategies directed at inhibition of PDGF-induced
SMC proliferation have been successfully tested in vitro and in
vivo (Table 1). These drugs are postulated to act at different
stages of PDGF-induced SMC proliferation (Fig. 2).
Drugs inhibiting PDGF release from platelets. Naft-
idrofuryl, used in the treatment of peripheral vascular
disease, and indomethacin have been reported to indepen-
dently inhibit platelet aggregation and PDGF release and
show an enhanced effect when combined in vitro (74). In a
small study designed to assess the efficacy of acetylsalicylic
acid as an anti-PDGF agent, platelet-rich plasma obtained
from healthy volunteers 12 h after oral acetylsalicylic acid
administration showed inhibition of collagen-induced re-
lease of PDGF; however, no effect on the release from
alpha-granules in serum was demonstrated (75). The sig-
nificance of this observation is not reported. In clinical
studies, acetylsalicylic acid did not reduce the restenosis rate
after angioplasty (46).
Drugs acting on the PDGF receptor. The structure of the
PDGF receptor includes a ligand-binding domain in the
extracellular portion and a tyrosine kinase region in the
intracellular portion. Drugs acting on the PDGF receptor
may interfere with binding of PDGF with its receptor or act
through inhibition of tyrosine kinase. Trapidil (triazolopy-
rimidine), a PDGF antagonist, exerts its effect by compet-
itive PDGF receptor blockade (76). Trapidil is also reported
to interfere with the regulation of PDGF-beta receptor
transcript levels (77); in addition, trapidil is a thromboxane
A2 antagonist (78).
A meta-analysis of trapidil has shown that trapidil could
reduce restenosis by 40% to 53% (79). A large study of
trapidil using intravascular ultrasound (Trapidil vs. Placebo
to Prevent In-Stent intimal hyperplasia [TRAPIST] study)
failed to demonstrate any beneficial effect on restenosis (80).
Another approach has been the application of antisense
oligonucleotides (AS-OLN) in the prevention of restenosis.
These oligonucleotides prevent messenger ribonucleic acid
(mRNA) translation into protein by hybridizing with the
targeted mRNA sequence (81). Use of AS-OLN may be
associated with toxic effects such as bone marrow suppres-
sion and inhibition of synthesis of intracellular proteins
(82). Use of AS-OLN against the PDGF receptor was first
reported by Sirois et al. (83); local perivascular administra-
tion in rat carotid arteries of AS-OLN to the PDGF-beta
receptor resulted in nearly complete inhibition of expression
of PDGF-beta receptor. Intimal thickening was reduced by
almost 80%, and precise correlation was found between
neointimal proliferation and PDGF-beta receptor expres-
sion.
Figure 2. Brief representation of possible mode of action of PDGF
on SMC leading to restenosis. Numbers in parentheses indicate
sites of action of various anti-PDGF drugs, as listed in Table 1.
(Note: because this is only a schematic representation, it is not
possible to show the site of action of all the drugs listed in Table
1.) 1,2-DG 5 1,2-diacylglycerol; IP3 5 inositol triphosphate;
PKC 5 protein kinase C; PTK 5 protein tyrosine kinase.
Table 1. Successfully Tested Anti-PDGF Agents
Naftidrofuryl
Indomethacin
Acetylsalicylic acid
Trapidil
Antisense oligonucleotides
Angiopeptin
PD 089828
Tyrophostins
Troglitazone
SCH 13929
Calcium antagonists
Pemirolast and tranilast
Bromocriptine
Vitamin E
Rapamycin
Prostaglandin E1
Paclitaxel
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Angiopeptin, a long-acting somatostatin analogue, is
reported to inhibit PDGF-induced vascular SMC prolifer-
ation (14). This compound activates specific protein ty-
rosine phosphatases that deactivate the phosphorylated
PDGF receptor proteins (84). Tyrosine kinase inhibitors
have also been investigated in the therapy of restenosis. PD
089828, which belongs to the 6-aryl-pyrido-(2,3-
d)pyrimidines, has demonstrated long-lasting and reversible
inhibition of PDGF-stimulated DNA synthesis and
PDGF-induced migration and proliferation of vascular
SMCs (85). Other tyrosine kinase blockers such as tyro-
phostins AG 1295 and AG 1296 also show selective
inhibition of PDGF (86). Troglitazone, an insulin-
sensitizing agent of the thiazolidinedione class, has been
reported in in vivo experiments to produce nearly 66% less
vascular SMC proliferation; in the same study, troglitazone
also inhibited PDGF-induced vascular SMC migration in
vitro (87). The authors suggest that inhibition of tyrosine
kinase–dependent growth factor action by troglitazone
inhibits migration and proliferation of vascular SMCs.
Another compound, SCH 13929 (2-bromomethyl-5-
chlorobenzene sulfonylphthalimide), inhibits PDGF-
induced migration and proliferation of SMCs by inhibiting
binding of PDGF with its receptor owing to the interaction
with the ligand (88). The potential of these compounds for
prevention of restenosis remains to be proven.
Drugs inhibiting intracellular (SMC) effects of PDGF.
The antioxidant vitamin E has been reported to inhibit
PDGF activity in vitro (89); these authors suggest that
vitamin E may inhibit protein kinase C activity and, by
preventing low density lipoprotein modification and uptake
by macrophages, may inhibit the release of PDGF. Calcium
antagonists have also been tried, because PDGF-induced
intracellular calcium flux (resulting from stimulation of
diglyceride formation) is considered an important compo-
nent in postreceptor signaling pathways (90). A meta-
analysis of five randomized trials involving 919 patients
showed a reduction of 30% in the relative risk of developing
restenosis after PTCA (91). Another trial, the Coronary
AngioPlasty Amlodipine in REStenosis (CAPARES) trial,
has been designed to assess the influence of calcium antag-
onists on restenosis (92).
In a rat model, orally administered pemirolast or tranilast
(antiallergic agents) started two days before arterial injury
significantly reduced the extent of neointimal proliferation
and intimal thickening (93); inhibition of activation of
phospholipase C may be the mechanism of action, as
phospholipase C is essential for cell proliferation stimulated
by PDGF (94). In human trials, patients treated with
pemirolast had significantly lower restenosis rates as com-
pared with control subjects (95). Another compound dem-
onstrated to have anti-PDGF activity is bromocriptine. In
an in vitro study, bromocriptine significantly inhibited the
proliferation of rat vascular SMCs (96). The inhibitory
effect of bromocriptine on protein kinase C is postulated as
a possible mode of anti-PDGF action, as protein kinase C
is involved in PDGF-induced vascular SMC proliferation
(97). The authors of that study also suggest that because
bromocriptine is a serotonin antagonist, the antiproliferative
effect could also result from the inhibition of stimulatory
effect of serotonin on vascular SMCs. Rapamycin, an
immunosuppressive agent of the macrolide group, has
shown to exert an antiproliferative effect on rat aortic wall
SMCs by inhibiting PDGF-induced vascular DNA synthe-
sis—an effect postulated to occur by preventing cells from
progressing from the G1 to S phase of the cell cycle (98).
Other drugs that inhibit PDGF-induced SMC prolifer-
ation. Drugs that are not direct inhibitors of the PDGF
pathway also inhibit PDGF-induced SMC proliferation.
Prostaglandin E1, given as a continuous infusion after
arterial injury in rats, significantly inhibited neointimal
proliferation (99). Suppression of leukocyte activation
(which can release PDGF) and increased intracellular cyclic
adenosine monophosphate (which suppresses vascular SMC
growth) are considered to be responsible for the effects of
prostaglandin E1 on vascular SMCs (100). Finally, pacli-
taxel, a drug developed for therapy of breast and ovarian
cancer, has also demonstrated an anti-PDGF effect in
experimental studies. Paclitaxel induces the formation of
abnormally stable and nonfunctional microtubules, leading
to inhibition of cell replication (101). In a recent report,
paclitaxel was shown to produce dose-dependent inhibition
of PDGF-induced human arterial SMC migration and
proliferation (102). In the same report, rabbits treated with
local paclitaxel after balloon angioplasty showed signifi-
cantly less neointimal proliferation and lower restenosis.
Conclusions. Of the three major factors contributing to
restenosis after PTCA, elastic recoil and vessel wall remod-
eling have been addressed by the advent of stents. There is
no effective therapy yet for the problem of neointimal
proliferation, with the possible exception of brachytherapy.
Platelets, by their capacity to adhere to the sites of arterial
injury, to form aggregates and to secrete highly potent
growth factors, the most important of which is PDGF,
appear to play an important role in neointimal proliferation
and development of restenosis. Many novel drugs and
delivery systems targeted at platelets have shown success in
experimental studies. However, the beneficial effects of the
various drugs tested successfully in experimental studies
have yet to be translated into a significant reduction in
restenosis. The use of drug-encapsulated platelets and sys-
temic or local delivery of anti-PDGF agents that inhibit the
various levels of action of PDGF appear to hold promise in
the prevention of restenosis.
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